Department of Neuropsychiatry, Faculty of Medicine, Tottori University, Yonago, Japan.
Neuropsychopharmacol Rep. 2020 Dec;40(4):383-387. doi: 10.1002/npr2.12142. Epub 2020 Sep 29.
Non-24-hour sleep-wake disorder (N24SWD) is often observed in the visually impaired and those who isolate indoors. Melatonin receptor agonists may be used for treatment, but there is currently no evidence that they are effective in patients without visual impairment.
We report a case of a 23-year-old woman who withdrew from her social life owing to autism spectrum disorder and experienced an unusual sleep rhythm. She presented with N24SWD. The N24SWD cycle averaged 25.6 days but was extended to 42 days using ramelteon. However, this was not enough. We prescribed the addition of suvorexant and the sleep cycle returned to normal.
N24SWD is a disease that seriously impairs social life and productivity. We propose a possible treatment strategy for N24SWD using ramelteon and suvorexant.
非 24 小时睡眠-觉醒障碍(N24SWD)常发生于视障人群和长期室内隔离人群。褪黑素受体激动剂可能对此有治疗效果,但目前尚无证据表明其对视障人群以外的患者有效。
我们报告了一例 23 岁女性病例,该患者因自闭症谱系障碍而退出社交生活,出现异常睡眠节律。患者表现为 N24SWD。N24SWD 周期平均为 25.6 天,但使用雷美替胺后延长至 42 天。然而,这还不够。我们建议加用苏沃雷生,此后睡眠周期恢复正常。
N24SWD 是一种严重影响社交和生产力的疾病。我们提出了一种使用雷美替胺和苏沃雷生治疗 N24SWD 的可能策略。